| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2500330 | Farmacia Hospitalaria | 2009 | 7 Pages |
Abstract
In B-CLL patients, treatment with oral fludarabine has a lower cost than treatment with intravenous fludarabine, in both single-drug therapy and combined therapy. Various sensitivity analyses confirmed these results and showed that oral fludarabine should be the treatment of choice for B-CLL in Spain, unless contraindicated.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
Julio Delgado, Laia Febrer, Diana Nieves, Carme Piñol, Max Brosa,